Peregrine Pharmaceuticals CEO Roger Lias receives $704K in 2018
Peregrine Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: August 17, 2018
Peregrine Pharmaceuticals reported fiscal year 2018 executive compensation information on August 17, 2018.
In 2018, five executives at Peregrine Pharmaceuticals received on average a compensation package of $573K, a 20% decrease compared to previous year.
Average pay of disclosed executives at Peregrine Pharmaceuticals
Roger J. Lias, Chief Executive Officer, received $704K in total. 57% of Lias' compensation, or $403K, was in option awards. Lias also received $245K in salary and $56K in other compensation.
Steven W. King, Chief Executive Officer, received a compensation package of $685K, which decreased by 37% compared to previous year. 55% of the compensation package, or $374K, was in salary.
Joseph S. Shan, Former Vice President, Clinical & Regulatory Affairs, earned $601K in 2018, a 18% increase compared to previous year.
Paul J. Lytle, Chief Financial Officer, received $463K in 2018, which decreases by 34% compared to 2017.
Mark R. Ziebell, General Counsel, earned $409K in 2018, a 30% decrease compared to previous year.
Peregrine Pharmaceuticals' fiscal year ends on April 30.
Related executives
Roger Lias
Peregrine Pharmaceuticals
Chief Executive Officer
Steven King
Peregrine Pharmaceuticals
Chief Executive Officer
Paul Lytle
Peregrine Pharmaceuticals
Chief Financial Officer
Joseph Shan
Peregrine Pharmaceuticals
Former Vice President, Clinical & Regulatory Affairs
Mark Ziebell
Peregrine Pharmaceuticals
General Counsel
You may also like
Source: SEC filing on August 17, 2018.